Anavex Life Sciences Corp (AVXL)

[falconer66a]

Super Response Factors

A number of patients on Anavex 2-73 have been designated "super responders," where their Alzheimer's symptoms declined and they attained or approached normal cognition, sleep patterns, and other super outcomes.

Why? Several factors could be at play.

First, it may be that Anavex 2-73 simply works extremely well in just a portion of all who suffer from Alzheimer's. If that's so, coupled with the superior safety profile determined in the Australian Phase1/Phase2 trial, the drug will be approved by FDA. In this case, it will be a winner for Anavex Life Sciences Corp, its shareholders, and a good percentage of Alzheimer's victims.

Or, super responses don't occur until a certain, perhaps longer dosing period is experienced. It may well be that when Anavex 2-73 is taken for a year or two, favorable outcomes begin appearing only toward the ends of those lengthy dosing periods.

Related to that is dosage. Anavex 2-73 Alzheimer's efficacy may also be a result of proper dosing sizes or routines. Perhaps dosing needs to be slowly and incrementally increased over lengthy periods to attain super responses.

All of this, I should think, will be determined in the up-coming big Phase 3 study. High chance, I think, the percentage of "super responders" will be much greater, even perhaps universal with new, optimized dosing levels and durations.